270 related articles for article (PubMed ID: 10977127)
21. Effects of hepatocyte growth factor on cyclic nucleotide-dependent signaling and steroidogenesis in rat ovarian granulosa cells in vitro.
Zachow RJ; Woolery JK
Biol Reprod; 2002 Aug; 67(2):454-9. PubMed ID: 12135881
[TBL] [Abstract][Full Text] [Related]
22. "cAMP-specific" phosphodiesterase contributes to cGMP degradation in cerebellar cells exposed to nitric oxide.
Bellamy TC; Garthwaite J
Mol Pharmacol; 2001 Jan; 59(1):54-61. PubMed ID: 11125024
[TBL] [Abstract][Full Text] [Related]
23. Expression and activity of cGMP-dependent phosphodiesterases is up-regulated by lipopolysaccharide (LPS) in rat peritoneal macrophages.
Witwicka H; Kobiałka M; Siednienko J; Mitkiewicz M; Gorczyca WA
Biochim Biophys Acta; 2007 Feb; 1773(2):209-18. PubMed ID: 17141339
[TBL] [Abstract][Full Text] [Related]
24. Role of phosphodiesterase and protein kinase G on nitric oxide-induced inhibition of prolactin release from the rat anterior pituitary.
Velardez MO; De Laurentiis A; del Carmen Díaz M; Lasaga M; Pisera D; Seilicovich A; Duvilanski BH
Eur J Endocrinol; 2000 Aug; 143(2):279-84. PubMed ID: 10913949
[TBL] [Abstract][Full Text] [Related]
25. Cyclic GMP and regulation of cyclic nucleotide hydrolysis.
Sonnenburg WK; Beavo JA
Adv Pharmacol; 1994; 26():87-114. PubMed ID: 8038108
[TBL] [Abstract][Full Text] [Related]
26. [Changes in cyclic nucleotide metabolism in compensatory adrenal hypertrophy (following unilateral adrenalectomy)].
Iudaev NA; Afinogenova SA; Zhukova TV
Probl Endokrinol (Mosk); 1982; 28(6):59-66. PubMed ID: 6130520
[TBL] [Abstract][Full Text] [Related]
27. Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3.
Feijge MA; Ansink K; Vanschoonbeek K; Heemskerk JW
Biochem Pharmacol; 2004 Apr; 67(8):1559-67. PubMed ID: 15041473
[TBL] [Abstract][Full Text] [Related]
28. PDE4 and PDE5 regulate cyclic nucleotides relaxing effects in human umbilical arteries.
Santos-Silva AJ; Cairrão E; Morgado M; Alvarez E; Verde I
Eur J Pharmacol; 2008 Mar; 582(1-3):102-9. PubMed ID: 18234184
[TBL] [Abstract][Full Text] [Related]
29. Individual cerebellar Purkinje cells express different cGMP phosphodiesterases (PDEs): in vivo phosphorylation of cGMP-specific PDE (PDE5) as an indicator of cGMP-dependent protein kinase (PKG) activation.
Shimizu-Albergine M; Rybalkin SD; Rybalkina IG; Feil R; Wolfsgruber W; Hofmann F; Beavo JA
J Neurosci; 2003 Jul; 23(16):6452-9. PubMed ID: 12878685
[TBL] [Abstract][Full Text] [Related]
30. Cyclic AMP compartmentation due to increased cAMP-phosphodiesterase activity in transgenic mice with a cardiac-directed expression of the human adenylyl cyclase type 8 (AC8).
Georget M; Mateo P; Vandecasteele G; Lipskaia L; Defer N; Hanoune J; Hoerter J; Lugnier C; Fischmeister R
FASEB J; 2003 Aug; 17(11):1380-91. PubMed ID: 12890691
[TBL] [Abstract][Full Text] [Related]
31. Cyclic nucleotide phosphodiesterase activity in patients with obstructive airways disease.
Polson JB; Krzanowski JJ; Goldman AL; Szentivanyi A
Allergol Immunopathol (Madr); 1982; 10(2):101-4. PubMed ID: 6125092
[TBL] [Abstract][Full Text] [Related]
32. Potency and mechanism of action of E4021, a type 5 phosphodiesterase isozyme-selective inhibitor, on the photoreceptor phosphodiesterase depend on the state of activation of the enzyme.
D'Amours MR; Granovsky AE; Artemyev NO; Cote RH
Mol Pharmacol; 1999 Mar; 55(3):508-14. PubMed ID: 10051534
[TBL] [Abstract][Full Text] [Related]
33. [Modern representations of multiple forms of cyclic nucleotide phosphodiesterases in mammalian tissues].
Medvedeva MV
Biokhimiia; 1995 Mar; 60(3):364-86. PubMed ID: 7734612
[TBL] [Abstract][Full Text] [Related]
34. Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis.
Piazza GA; Thompson WJ; Pamukcu R; Alila HW; Whitehead CM; Liu L; Fetter JR; Gresh WE; Klein-Szanto AJ; Farnell DR; Eto I; Grubbs CJ
Cancer Res; 2001 May; 61(10):3961-8. PubMed ID: 11358813
[TBL] [Abstract][Full Text] [Related]
35. Implications of PDE4 structure on inhibitor selectivity across PDE families.
Ke H
Int J Impot Res; 2004 Jun; 16 Suppl 1():S24-7. PubMed ID: 15224132
[TBL] [Abstract][Full Text] [Related]
36. Carboxyamidotriazole: a novel inhibitor of both cAMP-phosphodiesterases and cGMP-phosphodiesterases.
Guo L; Luo L; Ju R; Chen C; Zhu L; Li J; Yu X; Ye C; Zhang D
Eur J Pharmacol; 2015 Jan; 746():14-21. PubMed ID: 25446933
[TBL] [Abstract][Full Text] [Related]
37. The role of cGMP hydrolysing phosphodiesterases 1 and 5 in cerebral artery dilatation.
Kruuse C; Rybalkin SD; Khurana TS; Jansen-Olesen I; Olesen J; Edvinsson L
Eur J Pharmacol; 2001 May; 420(1):55-65. PubMed ID: 11412839
[TBL] [Abstract][Full Text] [Related]
38. Distinct profiles of phosphodiesterase isozymes in cultured cells derived from nonpigmented and pigmented ocular ciliary epithelium.
Bode DC; Hamel LT; Wax MB
J Pharmacol Exp Ther; 1993 Dec; 267(3):1286-91. PubMed ID: 8263791
[TBL] [Abstract][Full Text] [Related]
39. [Effect of several hormones on cyclic 3',5'-nucleotide phosphodiesterase in rat kidneys].
Iwase K
Nihon Naibunpi Gakkai Zasshi; 1983 Oct; 59(10):1678-91. PubMed ID: 6319206
[TBL] [Abstract][Full Text] [Related]
40. Regulation of intracellular cyclic GMP levels in olfactory sensory neurons.
Moon C; Simpson PJ; Tu Y; Cho H; Ronnett GV
J Neurochem; 2005 Oct; 95(1):200-9. PubMed ID: 16181424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]